TrialLeukemia & lymphoma2021

Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial.

Steven Horwitz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.